Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma.
Ram Vasudevan NampoothiriIvan PasicArjun Datt LawWilson LamCarol ChenFotios V MichelisDennis Dong Hwan KimArmin GerbitzJeffrey Howard LiptonRajat KumarJonas MattssonAuro ViswabandyaPublished in: European journal of haematology (2022)
Allogeneic HCT provides substantial long-term disease-free survival in a proportion of patients with MM-associated therapy-related hematological malignancies. Multicenter studies with more patients and longer follow-up may provide additional information about factors affecting outcomes.
Keyphrases
- allogeneic hematopoietic stem cell transplantation
- free survival
- multiple myeloma
- end stage renal disease
- ejection fraction
- newly diagnosed
- acute myeloid leukemia
- stem cell transplantation
- acute lymphoblastic leukemia
- bone marrow
- stem cells
- healthcare
- clinical trial
- low dose
- mesenchymal stem cells
- cross sectional
- signaling pathway
- health information
- adipose tissue
- skeletal muscle
- patient reported
- high dose
- cell death
- patient reported outcomes
- cell cycle arrest
- pi k akt
- glycemic control